JBC Transcription and Nuclear Factor Monoclonals

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M000711200 on May 23, 2000

J. Biol. Chem., Vol. 275, Issue 32, 24787-24797, August 11, 2000
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/32/24787    most recent
M000711200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Escalante, M.
Right arrow Articles by Birge, R. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Escalante, M.
Right arrow Articles by Birge, R. B.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Phosphorylation of c-Crk II on the Negative Regulatory Tyr222 Mediates Nerve Growth Factor-induced Cell Spreading and Morphogenesis*

Marcela EscalanteDagger §, Jody Courtney§, Wai Gong ChinDagger , Kenneth K. Teng, Jong-Il KimDagger , J. Eduardo FajardoDagger , Bruce J. Mayer**, Barbara L. Hempstead||, and Raymond B. BirgeDagger DaggerDagger

From the Dagger  Laboratory of Molecular Oncology, The Rockefeller University, New York, New York 10021,  Division of Hematology-Oncology, The New York Presbyterian Hospital-Weill Medical College of Cornell University, New York, New York 10021, and ** Howard Hughes Medical Institute, Children's Hospital, Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, Massachusetts 12115

Received for publication, January 27, 2000, and in revised form, May 1, 2000

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The Crk family of adaptor proteins participate in diverse signaling pathways that regulate growth factor-induced proliferation, anchorage-dependent DNA synthesis, and cytoskeletal reorganization, important for cell adhesion and motility. Using kidney epithelial 293T cells for transient co-transfection studies and the nerve growth factor (NGF)-responsive PC12 cell line as a model system for neuronal morphogenesis, we demonstrate that the non-receptor tyrosine kinase c-Abl is an intermediary for NGF-inducible c-Crk II phosphorylation on the negative regulatory Tyr222. Transient expression of a c-Crk II Tyr222 point mutant (c-Crk Y222F) in 293T cells induces hyperphosphorylation of paxillin on Tyr31 and enhances complex formation between c-Crk Y222F and paxillin as well as c-Crk Y222F and c-Abl, suggesting that c-Crk II Tyr222 phosphorylation induces both the dissociation of the Crk SH2 domain from paxillin and the Crk SH3 domain from c-Abl. Interestingly, examination of the early kinetics of NGF stimulation in PC12 cells showed that c-Crk II Tyr222 phosphorylation preceded paxillin Tyr31 phosphorylation, followed by a transient initial dissociation of the c-Crk II paxillin complex. PC12 cells overexpressing c-Crk Y222F manifested a defect in cellular adhesion and neuritogenesis that led to detachment of cells from the extracellular matrix, thus demonstrating the biological significance of c-Crk II tyrosine phosphorylation in NGF-dependent morphogenesis. Whereas previous studies have shown that Crk SH2 binding to paxillin is critical for cell adhesion and migration, our data show that the phosphorylation cycle of c-Crk II determines its dynamic interaction with paxillin, thereby regulating turnover of multiprotein complexes, a critical aspect of cytoskeletal plasticity and actin dynamics.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The Crk adaptor proteins, first described as the product of an avian oncogene, v-crk, contain Src homology 2 (SH2)1 and SH3 domains that serve as binding sites for a diverse set of signaling proteins (1-3). A number of studies with v-Crk have established a paradigm in which SH2 and SH3 domain-coupled signals positively regulate growth factor- (4-6) as well as integrindependent pathways (7, 8). Recent studies have also linked the cellular homologs of v-Crk, namely c-Crk I, c-Crk II, and CrkL (9, 10), with cellular proteins that induce Rac GDP-GTP exchange activity (11, 12), cytoskeletal reorganization (13), cellular migration (14), and anchorage-dependent cell growth (15). Although c-Crk and v-Crk may have some overlapping functions due to their SH2 and N-terminal SH3 domains, both c-Crk II and CrkL contain an additional SH3 domain in the C terminus (10, 16) as well as a conserved tyrosine (c-Crk II Tyr221 and CrkL Tyr207 in the human isoforms; c-Crk II Tyr222 in the avian isoform) that can be phosphorylated by the non-receptor tyrosine kinase c-Abl (17, 18). Moreover, c-Crk Tyr222 is flanked by an AQPS motif in the linker region, which when phosphorylated, conforms to a consensus Crk SH2 binding site and has been hypothesized to negatively regulate c-Crk function(s) by forming an intramolecular bridge (19). Although these studies suggest a model of c-Crk regulation that is analogus to that of Src family tyrosine kinases upon phosphorylation by C-terminal Src kinase (CSK) (20), the underlying mechanism by which phosphorylated Tyr222 modulates c-Crk II biological functions is not well understood.

Following their activation by binding to extracellular matrix molecules, integrins couple with intracellular tyrosine kinases such as FAK, Pyk2, Src, and c-Abl, leading to the formation of complex signaling networks involving kinases, their substrates, and adaptor proteins (21-25). Two of the major tyrosine-phosphorylated proteins that orchestrate the assembly of focal adhesions are paxillin and p130cas (26, 27). Although unrelated structurally, both genes encode multidomain proteins that can associate with and become phosphorylated by various nonreceptor tyrosine kinases (FAK, Src, CSK, and c-Abl for paxillin and FAK and Src family members for p130cas) (25, 28). Furthermore, after tyrosine phosphorylation, both paxillin and p130cas present multiple docking sites for the Crk SH2 domain (29-31), thereby recruiting additional signaling proteins to focal adhesions via the Crk N-terminal SH3 domain (3). Accordingly, the binding of DOCK180 to p130cas·Crk complex has been implicated in altering cell morphology via the activation of Rac1 (32), and mutations in either the Crk SH2 domain or the Crk-binding sites of p130cas have been shown to impair cell migration in carcinoma cells (14). Recently, it has also been shown that phosphorylation of Tyr31 and Tyr118 on paxillin regulates cell migration through an association of Crk in NBT-II cells (33), suggesting that Crk binding to paxillin and p130cas may have redundant functions.

Although integrin-mediated tyrosine phosphorylation of paxillin and p130cas has been best characterized, various growth factors including insulin, epidermal growth factor, and platelet-derived growth factor also induce rapid changes in cell shape that correlate with tyrosine phosphorylation of paxillin and p130cas (34-36). Although these results clearly support a model of cross-talk between receptor tyrosine kinases and molecules residing in focal adhesions, it remains unclear whether Crk proteins might be signaling intermediates that orchestrate these interactions. Using the PC12 cells as a model system of nerve growth factor (NGF)-induced neuronal morphogenesis (37), we and others have previously shown that NGF induces rapid actin reorganization and membrane ruffling that accompany alterations in cell shape (38), with concomitant tyrosine phosphorylation of c-Crk II and paxillin (4, 39). In the present study, we describe a novel pathway in which activation of the NGF receptor Trk A leads to c-Abl-mediated phosphorylation of c-Crk II at Tyr222, which catalyzes the dissociation of the Crk SH2 domain from paxillin and the dissociation of the Crk SH3 domain from c-Abl. The significance of this mechanism is highlighted by the findings that a c-Crk II Tyr222 mutant (c-Crk Y222F), while causing constitutive complex formation between c-Crk and paxillin as well as c-Crk and c-Abl, impairs NGF-dependent cellular spreading and neurite outgrowth. Thus, although previous studies have indicated that Crk binding to paxillin and p130cas is critical for cell adhesion and motility, we propose that the dynamic nature of substratum adhesion and detachment, a critical aspect of NGF-induced morphogenesis, is determined in part by the phosphorylation/dephosphorylation cycle of c-Crk II on Tyr222.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cells and Tissue Culture-- Fibroblasts immortalized from Abl (-/-) or FAK (-/-) homozygous mice were generous gifts of David Baltimore (California Institute of Technology) and Tadashi Yamamoto (Tokyo University), respectively, and were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% calf serum. Abl (-/-) fibroblasts engineered to stably re-express wild-type c-Abl after DNA transfection with pBabe-c-Abl were a gift from Tohru Ouchi (Mount Sinai School of Medicine). Wild-type PC12 cells were maintained in DMEM supplemented with 10% calf serum and 5% horse serum. TrkA-overexpressing PC12-615 cells, c-Crk II overexpressing PC12 cells, and c-Crk Y222F-expressing PC12 cells were maintained in DMEM containing 10% calf serum and 5% horse serum with 200 µg/ml G418. 293T cells and Bosc23 ecotropic virus-packaging cell lines were grown in DMEM supplemented with 10% fetal calf serum.

Antibodies-- Anti-peptide polyclonal antibodies that recognize Tyr222-phosphorylated c-Crk II (pCrk) were provided by Michiyuki Matsuda (National Institute of Infectious Diseases, Tokyo, Japan) (40), and monoclonal anti-Src antibodies were from Joan Brugge (Harvard Medical School). Anti-TrkA polyclonal antibodies were generated as described previously (41). Commerically available antisera were purchased from the indicated sources: anti-phosphotyrosine (Tyr(P)) antibodies PY20 (Transduction Laboratories), 4G10 (Upstate Biotechnology, Inc.), and PY-99 (Santa Cruz Biotechnology); anti-FLAG monoclonal M2 (Eastman Kodak Co.); anti-c-Abl monoclonal 8E9 (Pharmingen) and anti-c-Abl monoclonal Ab-3 (Calbiochem); anti-paxillin monoclonal (Zymed Laboratories Inc. or Transduction Laboratories); anti-FAK, anti-c-Crk II, and anti-p130cas (all from Santa Cruz Biotechnology).

Plasmid Constructions and DNA Transfection-- The c-crk II, c-abl, and trkA plasmids and respective mutants have been previously described. Briefly, avian c-crk II and c-crk Y222F were subcloned into the pEBG vector, driven by the human elongation factor 1-alpha promotor (42). Wild-type and kinase-deficient (K290M) murine type IV c-abl (43) were provided by David Baltimore as described previously (44) and were subcloned into pcDNA3 (Invitrogen). Expression plasmids for TrkA (pcDNA3-trkA), kinase-dead c-Src (pBabe K295M src), or kinase-dead FAK (pCR K454M FAK) were provided by David Kaplan (McGill University), Hisataka Sabe (Osaka Bioscience institute), and Steven Hanks (University of Virginia), respectively. To construct a FLAG epitope-tagged paxillin expression vector, a full-length chicken paxillin cDNA in pGEX (26) was digested with BamHI and then subcloned into pFLAG-CMV2 (Eastman Kodak) using BamHI-EcoRI linkers. Site-directed mutagenesis was performed using the QuikChange site-directed mutagenesis kit (Stratagene). The following sequences (5'-3') of the sense mutagenic oligonucleotides were used, with mismatches indicated in uppercase: for the Y31F mutation, gag gaa acg cct tTc tcc tac cca act g; for Y118F, gag gaa cac gtg tTc agc ttc cca aac; and for Y182F, g acc gga cct cac tT t gtc atc cca gag. All point mutations were confirmed by DNA sequencing.

To generate clonal PC12 cell lines stably overexpressing Crk protein, cells were transfected with 18 µg of pEBG-c-Crk II or pEBG-c-Crk Y222F plasmid DNA and 2 µg of pMEXneo using the LipofectAMINETM reagent (Life Technologies, Inc.), and cell lines were expanded as described previously (4). We found that a high level of c-Crk II or c-Crk Y222F expression was unstable in PC12 cells over multiple passage.2 Therefore, cell lines were routinely monitored for consistent levels of of c-Crk II or c-Crk Y222F expression, and when necessary, aliquots of early passaged lines were re-established from liquid nitrogen stocks. For transient transfections, subconfluent cultures of 293T cells were transfected for 4 h in serum-free Opti-MEM with plasmid DNAs using the LipofectAMINE reagent (Life Technologies, Inc.), and cells were lysed 48 h after transfection. Where applicable, 293T cells were stimulated with 100 ng/ml NGF (Collaborative Biomedical Sciences) in serum-free DMEM before lysis.

Generation of and Infections with Recombinant c-Crk-containing Retroviruses-- A cDNA encoding full-length c-Crk II or c-Crk Y222F was subcloned into a bicistronic pCX-bsr retroviral vector in which c-Crk II and green fluorescent protein (GFP) are expressed from the same transcript via an internal ribosome entry site. c-Crk-expressing virus was produced by LipofectAMINE-mediated transfection of 1.0 µg of pCX-crk DNA together with 1.0 µg of pC-Eco retroviral DNA into the Bosc23 replication incompetent ecotropic packaging line (RetromaxTM, Imgen) according to the manufacturer's protocols. Transfection media was replaced with 10 ml of DMEM containing 10% fetal calf serum for 24 h and then collected and frozen at -70 °C. The cells were re-fed with fresh DMEM (10 ml) and maintained for an additional 16 h. A total of 20 ml of virus-containing tissue culture media were pooled, centrifuged at 15,000 × g for 3 h, and resuspended into 2.0 ml of PC12 cell medium containing 7 µg/ml Polybrene. PC12 cells, seeded at 50% confluency, were infected with the concentrated stock for 48 h, and medium was changed and incubated for an additional 48 h. Between 20 and 30% PC12 cells were GFP-positive, and high levels of ectopic protein expression was detectable for up to 1 week.

Flow Cytometry and Fluorescence-activated Cell Sorter (FACS) Sorting-- PC12 cells were incubated with phosphatidylethanolamine-conjugated anti-Annexin V (Chemicon) in the binding buffer (5 mM CaCl2, 140 mM NaCl, 10 mM Hepes, pH 7.4) for 30 min at 4 °C, and stained cells were analyzed using FACScan. For sorting, PC12 cells infected with each GFP expression vector were sorted by green fluorescence using FACStarPlus (Becton Dickinson Inc, San Jose, CA). For analysis of adherent and non-adherent pools, PC12 cells were infected with pCX virus, and 3 days after infection, poorly adherent cells were collected by gentle trituration and pooling the media after washing in PBS. The adherent cells were harvested mechanically in PBS containing 10 mM EDTA. The ratio of total GFP-positive cells in each population was quantified by flow cytometry.

Immunoprecipitation and Western Blotting-- 293T cells were lysed in ice-cold HNTG buffer (20 mM Hepes, pH 7.5, 150 mM NaCl, 10% glycerol, and 1% Triton X-100) containing 0.1 mM sodium molybdate, 1 mM sodium vanadate, 1 mM phenylmethylsulfonyl fluoride, and 10 µg/ml aprotinin. PC12 cells were lysed in TLB buffer (1% Nonidet P-40, 20 mM Tris, pH 7.5, 137 mM NaCl, 2 mM EDTA, 20 mM beta -glycerophosphate, 2 mM sodium pyrophosphate, and 10 mM NaF) containing phosphate and protease inhibitors. Cleared lysates were incubated with specific antibodies (typically 1-2 µg) for 3 h at 4 °C followed by incubation with protein A-Sepharose beads (Amersham Pharmacia Biotech) or protein G plus-Sepharose (Santa Cruz Biotechnology). After washing with lysis buffer, immune complexes were subjected to SDS-PAGE and Western blot analysis using standard protocols. Blots were incubated with the indicated primary antibodies and the appropriate horseradish peroxide-conjugated secondary antibodies, followed by detection using enhanced chemiluminescence (ECL) reagent (Renaissance, NEN Life Science Products).

Protein Kinase Assays-- Immune complex kinase assays for c-Abl were performed using [gamma -32P]ATP and GST-Crk 120-225 as an exogenous substrate as described previously (17). After 20 min at room temperature, kinase reactions were terminated by boiling in SDS sample buffer before SDS-polyacrylamide gel electrophoresis. Gels fixed in 50% methanol, 10% acetic acid were subjected to autoradiography. Quantification of kinase activity was performed using a Molecular Dynamics Phospho-Imager.

Immunofluorescence and Confocal Microscopy-- Wild-type PC12 and c-Crk II- or c-Crk Y222F-expressing PC12 cells were plated on glass coverslips coated with collagen type IV and cultured in the presence of NGF for the indicated times (5). After rinsing with PBS, cells were fixed at room temperature for 30 min in 3% paraformaldehyde, permeabilized with 0.2% Triton X-100 for 5 min, and incubated with anti-paxillin monoclonal antibody (Zymed Laboratories Inc., diluted 1:200 in PBS containing 0.2% gelatin). After washing, cells were incubated with fluorescein-conjugated goat anti-mouse IgG (1:200 dilution). To detect F-actin, cells were incubated with rhodamine-conjugated phalloidin (Molecular Probes;1:200 dilution) for 30 min, washed in PBS, and mounted in Vectashield (Vector Labs). To assess the extent of plasma membrane flattening, cells were labeled with BSA-conjugated DiI (kindly provided by Sushmita Mukherjee, Weill Medical College of Cornell University) for 1 min, washed in PBS, and immediately fixed in 3% paraformaldehyde. Cells were examined with an epifluorescence microscope at 100× (Nikon) or with a confocal laser-scanning microscope (Bio-Rad) using 60× objective, generating 0.54-µm sections. Serial X-Y sections obtained from the confocal microscope were reanalyzed in the x-z plane using NIH Image software to make height and area measurements. Height measurements were made by averaging the height of three z-sections per cell. Area measurements were calculated by tracing the outline of a representative slice.

Cell Adhesion Assays-- Cell attachment was assessed according to the methods of Tomaselli (45). Briefly, PC12 cells were plated in 96-well flat-bottomed plates coated with BSA (1 mg/ml), poly-D-lysine (1 mg/ml), or collagen IV (2 mg/ml). Cells were incubated in media containing 3% serum and 100 ng/ml NGF for 6 h at 37 °C. Unattached cells were dislodged from the bottom of the well by three washes in PBS. Attached cells were fixed in glutaraldehyde and stained with 0.5% trypan blue. Quantitation of attached cells was performed by measuring absorbance at 590 nm of individual wells using a microtiter plate reader. Each value represents the mean and S.D. of determinations made on triplicate cultures performed in parallel and is expressed as a percentage of cell attachment on the indicated substrate relative to the cell attachment to poly-D-lysine.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Stimulation of Cells with NGF Induces Phosphorylation of Paxillin on Tyr31 and c-Crk II on Tyr222-- When PC12 cells are stimulated to differentiate with NGF, multiple proteins, including c-Crk II and paxillin, become tyrosine-phosphorylated within minutes after growth factor stimulation (4, 39, 46). To identify the residues on paxillin and c-Crk II that are tyrosine-phosphorylated following NGF stimulation, Tyr to Phe point mutants of paxillin or c-Crk II were co-expressed with the NGF receptor TrkA in human epithelial kidney (HEK) 293T cells (Fig. 1). Mutagenesis of the three putative high affinity Crk SH2 binding motifs in the N-terminal region of paxillin (Tyr31-Ser-Tyr-Pro, Tyr118-Ser-Phe-Pro, and Tyr182-Val-Ile-Pro (26)) virtually abrogated NGF-inducible paxillin phosphorylation (Fig. 1A, lanes 2 versus 3). To map the sites of NGF-inducible paxillin phosphorylation in more detail, Tyr31, Tyr118, and Tyr182 residues were mutated singly or in combination and co-expressed with TrkA in 293T cells (Fig. 1B). Paxillin mutants containing a Y31F substitution exhibited the most significant reduction (>70%) in Trk A-dependent phosphorylation after NGF treatment (Fig. 1B), whereas a Y113F,Y182F paxillin double mutant with an intact Tyr31 was less affected. To demonstrate that Tyr31 represents the major NGF-inducible Crk binding motif in paxillin, 293T cells co-expressing TrkA and c-Crk II with either FLAG-tagged paxillin, FLAG-tagged Y31F paxillin, or FLAG-tagged paxillin Y31F,Y118F,Y182F paxillin, were immunoprecipitated with anti-Crk antibodies (Fig. 1C). As indicated, mutation of Tyr31 in paxillin significantly disrupted binding to c-Crk II, which was not further abrogated upon co-expression of Y31F,Y118F,Y182F paxillin with TrkA and c-Crk II (Fig. 1C, inset). These results indicate that paxillin Tyr31 is the major site mediating c-Crk II interaction following NGF stimulation in vivo.


View larger version (39K):
[in this window]
[in a new window]
 
Fig. 1.   Mapping of the NGF-inducible tyrosine phosphorylation sites on paxillin and c-Crk II. A, each of the three putative Crk SH2 binding tyrosines in paxillin, Tyr31, Tyr118, and Tyr182, was mutated to phenylalanine (paxillin 3Y right-arrow 3F). 293T cells were cotransfected with 1.0 µg of cDNA encoding TrkA and 0.2 µg of either wild-type FLAG-tagged paxillin or mutant as indicated. After 48 h, cells were stimulated with 100 ng/ml NGF, and cellular lysate (500 µg) was immunoprecipitated with 1.0 µg of anti-FLAG antibody (M2). Complexes were resolved by SDS-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes, and blots were probed with either anti-FLAG, anti-paxillin, or anti-Tyr(P) (anti-pTyr) as indicated. B, 293T cells were co-transfected as in panel A with TrkA and either wild-type paxillin or one of the paxillin mutants indicated. Subsequently, cells were stimulated with NGF, and total cellular lysate was immunoblotted (20 µg protein) with anti-Tyr(P) antibody to compare tyrosine phosphorylation of individual paxillin mutants. The blot was then reprobed with anti-FLAG antibody (M2) or anti-phospho-TrkA (pTrkA) to verify expression. C, NGF-inducible Tyr31 phosphorylation on paxillin is the principal site for c-Crk II binding. 293T cells expressing TrkA and c-Crk II with either FLAG-tagged wild-type paxillin or the paxillin triple mutant (paxillin Y right-arrow F) were immunoprecipitated with an anti-Crk antibody and immunoblotted with either anti-Tyr(P) or anti-FLAG antibodies. Loading controls for the amount of paxillin, Crk, and phospho-TrkA are shown in the lower three panels. In the inset, the relative binding of c-Crk II to wild-type paxillin, Y31F paxillin, or Y31F,Y118F,Y182F paxillin is compared. Immunoblots were quantified by laser densitometric scanning of the films. D, 293T cells were co-transferred with 1.0 µg of cDNA encoding TrkA and 0.2 µg of either c-Crk II or c-Crk Y222F constructs as indicated. After 48 h, cells were treated with 100 ng/ml NGF for 5 min, and the lysates were immunoblotted with either anti-phospho-Crk (anti-pCrk) or anti-Tyr(P) antibodies. The blot was then reprobed with anti-Crk and anti-TrkA antibodies to verify expression (bottom panels). WB, Western blotting; IP, immunoprecipitation.

Although Tyr222 is a major site for c-Crk II phosphorylation in vitro (17), we sought to verify that the same tyrosine residue becomes tyrosine phosphorylated in vivo following TrkA activation. Toward this goal, wild-type c-Crk II or the point mutant of c-Crk II at Tyr222 (c-Crk Y222F) were coexpressed with TrkA in 293T cells. Using either an anti-phosphotyrosine (Tyr(P)) antisera or phospho-c-Crk-specific Tyr222 (pCrk) antisera, we found that wild-type c-Crk II, but not c-Crk Y222F, was phosphorylated upon NGF treatment (Fig. 1D, compare lanes 2 and 3 in respective panels). Together, these observations suggest that c-Crk II is phosphorylated exclusively on Tyr222 upon NGF stimulation in vivo.

NGF-inducible Tyrosine Phosphorylation of c-Crk II and of Paxillin Requires c-Abl-- A recent study by Yano et al. (47) reports an interaction between c-Abl and TrkA in both PC12 cells and after cotransfection into 293T cells. Since c-Abl is known to interact with c-Crk II (17) and with paxillin (23), it may be a likely candidate to mediate the NGF-induced tyrosine phosphorylation of these proteins. To assess the role of c-Abl in NGF-induced c-Crk II phosphorylation, c-Crk II and TrkA were coexpressed in fibroblasts derived form Abl (-/-) mice. Whereas c-Crk Tyr222 was readily phosphorylated in NGF-stimulated PC12 cells (39) or in 293T cells co-expressing c-Crk and TrkA (Fig. 1D), NGF treatment of Abl (-/-) fibroblasts expressing TrkA and c-Crk II did not lead to detectable c-Crk II phosphorylation (Fig. 2A, lane 3). However, when wild-type c-Abl expression was reconstituted in Abl (-/-) fibroblasts by stable gene transfer (Fig. 2A, Abl kinase panel), NGF-induced c-Crk II phosphorylation was also restored (Fig. 2A, lane 4). c-Crk II Tyr222 was not readily detectable in Abl-reconstituted Abl (-/-) fibroblasts in the absence of TrkA expression and NGF stimulation (Fig. 2A, inset). These results suggest that c-Abl is likely an intermediary kinase responsible for c-Crk II tyrosine phosphorylation following NGF stimulation.


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 2.   c-Abl is required for NGF-inducible c-Crk II and paxillin tyrosine phosphorylation. A, c-Abl null (-/-) fibroblasts were transfected with TrkA and c-Crk II constructs as indicated. Abl kinase assay was performed as described (top panel; Ref. 17). In lane 4, c-Abl-deficient cells were stably transfected with pBabe-c-Abl to obtain c-Abl-reconstituted (Abl +/+) cells. In the lower two panels, lysates were immunoblotted with anti-Crk or anti-Tyr(P) (anti-pTyr) antibodies as indicated to verify c-Crk expression and tyrosine phosphorylation. In the inset, the extent of c-Crk Tyr222 phosphorylation (*) in Abl (-/-) cells in the presence or absence of TrkA is indicated. B, stable association of paxillin and c-Abl. 293T cells were cotransfected with cDNAs encoding FLAG-tagged paxillin and one of the plasmids indicated. Cell lysates were either immunoblotted with anti-Tyr(P) to compare paxillin tyrosine phosphorylation or reprobed with anti-FLAG antibody to verify paxillin expression. In the lower two panels, extracts were immunoprecipitated with anti-FLAG antibody, divided into equal aliquots, and analyzed for Abl kinase activity (Abl kinase assay) or immunoblotted with anti-c-Abl antibody 8E9 to verify expression (anti-Abl WB). C, control mouse embryo fibroblasts (MEF) (lanes 1 and 2) or FAK (-/-) fibroblasts (lanes 3 and 4) were transfected with FLAG-tagged paxillin in the presence or absence of TrkA construct as indicated. After NGF stimulation, protein extracts were immunoblotted with anti-Tyr(P) to compare paxillin tyrosine phosphorylation (top panel). The blot was then reprobed with anti-FAK and anti-FLAG antibodies to verify appropriate protein expression (lower two panels). D, c-Abl, but not FAK or Src, mediates Trk A-dependent paxillin phosphorylation. 293T cells were contransfected with vectors encoding paxillin and TrkA and one of the kinase-deficient constructs encoding c-Abl (K290M), FAK (K454M), or c-Src (K416M) as indicated. Cell lysates were immunoblotted with anti-Tyr(P) to compare paxillin tyrosine phosphorylation. The blot was sequentially reprobed with the indicated antibodies to verify appropriate kinase expression. WB, Western blotting; IP, immunoprecipitation.

To determine whether NGF-inducible paxillin tyrosine phosphorylation is also dependent on c-Abl, FLAG-tagged paxillin and TrkA were transiently co-expressed with either wild-type c-Abl or the kinase-deficient mutant K290M c-Abl (Fig. 2B). Overexpression of wild-type c-Abl results in high levels of tyrosine phosphorylation of paxillin, which was not significantly augmented by TrkA expression (Fig. 2B, lanes 2 versus 3, Tyr(P) (anti-pTyr) blot). However, expression of K290M c-Abl abolished the phosphorylation of paxillin following Trk A activation (lane 4). Indeed, both wild-type and K290M c-Abl formed stable complexes with paxillin in co-precipitation analysis (Fig. 2B, anti-Abl blot; lanes 2-4), although as expected, no paxillin-associated kinase activity was detected when K290M c-Abl was expressed (Fig. 2B, Abl kinase assay; lane 4).

Other nonreceptor tyrosine kinases such as FAK and Src have been implicated in the integrin-dependent tyrosine phosphorylation of paxillin on Tyr31 and Tyr118 (30, 48), which in turn create Crk SH2 binding sites (29, 30). While the results in Fig. 2B demonstrate that c-Abl can also phosphorylate paxillin, it is not clear whether c-Abl also requires FAK or Src following TrkA activation. To address this, mouse embryo fibroblasts (MEF) derived from wild-type or FAK (-/-) embryos (49) were cotransfected with TrkA and wild-type paxillin (Fig. 2C). Trk A-dependent tyrosine phosphorylation of paxillin was evident in FAK (-/-) cells, and the extent of phosphorylation was similar in cells expressing or lacking FAK (Fig. 2C, lanes 2 and 4). Moreover, when paxillin was co-transfected with TrkA in 293T cells in the presence of either kinase-deficient c-Abl (K290M c-Abl), kinase-deficient FAK (K454M FAK), or kinase-deficient-Src (K295M c-Src), K290M c-Abl exhibited the most significant inhibition in Trk A-induced paxillin phosphorylation (Fig. 2D). These results suggest that different activating stimuli may utilize distinct intermediate non-receptor tyrosine kinases for the tyrosine phosphorylation of paxillin; Src and FAK for integrin and c-Abl for NGF.

Complex Formation between c-Crk II and Paxillin and c-Crk II and Abl Is Regulated by c-Crk II Tyr222 Phosphorylation-- Whereas the phosphorylation of Tyr31 in paxillin induces an association between Crk and paxillin (Fig. 1C), Tyr222 phosphorylation in c-Crk II induces an intramolecular association of the Crk SH2 domain and is expected to lead to a dissociation of Crk from paxillin (17). To examine the effect of c-Crk Tyr222 phosphorylation on the cellular turnover of Crk/paxillin complexes, 293T cells co-expressing TrkA, FLAG-tagged paxillin, and wild-type c-Crk II or Y222F c-Crk were analyzed (Fig. 3). Expression of c-Crk Y222F resulted in an increased level of cellular paxillin tyrosine phosphorylation (Fig. 3A, lanes 2 and 3 in anti-Tyr(P) (anti-pTyr) blot), and a much greater proportion of the total pool of c-Crk Y222F existed as a complex with paxillin compared with the wild-type c-Crk II, as evident from co-immunoprecipitation analysis (Fig. 3B). Interestingly, only the unphosphorylated pool of c-Crk II interacted with paxillin, and the Tyr222-phosphorylated pool of c-Crk II was found exclusively in the supernatant. These results suggest that at steady state, there is an equilibrium between two separate pools of c-Crk II: (i) unphosphorylated c-Crk II, which complexes with tyrosine-phosphorylated paxillin, and (ii) tyrosine-phosphorylated c-Crk II, which is monomeric.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 3.   Expression of c-Crk Y222F leads to increased paxillin tyrosine phosphorylation and results in enhanced Crk/paxillin association. A, 293T cells were cotransfected with plasmid vectors encoding FLAG-tagged paxillin and TrkA together with wild-type c-Crk II or c-Crk Y222F as indicated. After NGF stimulation, protein extracts (20 µg) were immunoblotted with anti-Tyr(P) (anti-pTyr) to compare paxillin tyrosine phosphorylation (top panel). The numbers in parentheses indicate the relative intensity of the immunopositive signal as determined by densitometry. The membrane was also reprobed with antibodies to FLAG, Crk, or pTrk to verify appropriate expression. B, c-Crk Y222F increases complex formation between Crk and paxillin. Lysates from 293T cell cotransfectants (Fig. 3A, lanes 2 and 3) were immunoprecipitated with anti-FLAG antibody, divided into equal aliquots, and immunoblotted with either anti-pCrk or anti-Crk antibodies. The top panel (anti-pCrk spnt) represents the supernatant fraction recovered from the anti-FLAG immunoprecipitation. WB, Western blotting; IP, immunoprecipitation.

Given the hyperphosphorylation of paxillin in cells expressing Y222F c-Crk II and the fact that paxillin can serve as a substrate for Abl following NGF stimulation, we investigated the effect of Y222F c-Crk II on the cellular interaction between c-Abl and the SH3 domain of Crk (Fig. 4A). When 293T cells expressing wild-type c-Abl and c-Crk Y222F were immunoprecipitated with anti-Crk antibodies, the activity of c-Abl associated with c-Crk Y222F was more than 4-fold greater than that associated with equivalent amounts of wild-type c-Crk II (Fig. 4A and inset), and importantly, there was much more Abl co-precipitating with c-Crk Y222F under these conditions (Fig. 4A, top panel). No Abl activity associated with the c-Crk W170K SH3 domain mutant (not shown), confirming previous studies that the interaction between Abl and Crk is dependent on the Crk SH3 domain (17). Interestingly, when replicate lysates to those used in Fig. 4A were immunoprecipitated with anti-FLAG antibodies (to precipitate paxillin), there was also a much greater pool of Abl co-precipitating with paxillin in c-Crk II Y222F-expressing 293T cells, as well as a greater pool of Crk in these complexes (Fig. 4B). Collectively, the results in Figs. 3 and 4 indicate that Crk Tyr222 phosphorylation actively induces both the dissociation of the Crk SH2 domain from paxillin and the Crk SH3 domain from Abl and that mutagenesis of the Tyr222 in c-Crk potentiates Abl-dependent paxillin tyrosine phosphorylation by inducing a persistent Crk/paxillin/Abl protein complex in cells.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 4.   Expression of c-Crk Y222F enhances the association of Crk with Abl and with paxillin. A, 293T cells were cotransfected with wild-type c-Abl and one of the c-Crk expression plasmids as indicated. Cellular lysates (1.0 mg of protein) were immunoprecipitated with anti-Crk antibody, divided into equal aliquots, and analyzed for for c-Abl/c-Crk co-immunoprecipitation and c-Abl kinase activity (top two panels). The blot was reprobed with anti-Crk antibodies to verify appropriate Crk protein expression in the immunoprecipitates. Total cellular lysates were Western-blotted with an anti-Abl antibody to verify c-Abl protein expression. In the inset, the gels were quantified with a Molecular Dynamics PhosphorImagerTM, and the data are expressed as average ± S.E. of three experiments. B, 293T cells were cotransfected with plasmid vectors encoding FLAG-tagged paxillin and the indicated plasmids. Cell lysates (1.0 mg of protein) were immunoprecipitated with an anti-FLAG antibody, and immune complexes were Western-blotted with the anti-cAbl antibody 8E9 or reprobed with anti-FLAG antibody to verify paxillin expression. The lower two panels showed the appropriate expression of c-Abl and wild-type c-Crk II or c-Crk Y222F in the total lysate. WB, Western blotting; IP, immunoprecipitation.

NGF-induced Dissociation of c-Crk II-Paxillin Complex in PC12 Cells Is Also Inhibited by c-Crk Y222F-- The transient transfection experiments in 293T cell system suggests a model in which c-Crk II Tyr222 phosphorylation is required for the regulated turnover of Crk-paxillin-Abl protein complexes. To test the biological importance of this model during neuronal differentiation, we first investigated the kinetics of c-Crk II and paxillin tyrosine phosphorylation in the NGF-treated PC12-615 cell line (41) (Fig. 5A). An early time course analysis revealed that whereas TrkA activation was detectable 1 min after NGF stimulation, tyrosine phosphorylation of c-Crk II was apparent by 2 min and persisted for at least 1 h, with an upward electromobility shift of c-Crk II (Fig. 5B). Although basal tyrosine phosphorylation of paxillin was observed in unstimulated cells (Fig. 5C, lane 1), NGF-augmented paxillin phosphorylation was detectable 5 min after NGF stimulation and maintained for up to 3 h after NGF treatment (Fig. 5C and data not shown).


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 5.   Effects of NGF on the kinetics of tyrosine phosphorylation of c-Crk II and paxillin in PC12 cells. A, serum-starved TrkA-expressing PC12-615 cells were stimulated with 100 ng/ml NGF for up to 60 min. Cells were then lysed and immunoblotted with anti-Tyr(P) (anti-pTyr) antibody. Tyrosine-phosphorylated TrkA, paxillin and the mitogen-activated protein kinases (ERK) are indicated on the right. B and C, the same lysates as shown in Fig. 6A were immunoprecipitated with either anti-Crk (B) or anti-paxillin (C) antibodies. The immune complexes were Western-blotted with anti-Tyr(P) antibodies to show NGF-inducible tyrosine phosphorylation and endogenous c-Crk II and paxillin to show expression. D, PC12-615 cells were infected with recombinant retroviral vectors for GFP (lane 1), wild-type c-Crk II (lanes 2 and 3), or c-Crk Y222F (lanes 4 and 5). After 48 h, cells were treated with or without 100 ng/ml NGF for 2 min and rapidly lysed in ice-cold HNTG buffer. The lysates were immunoprecipitated with anti-Crk antibody, and immunoblotted with an anti-paxillin antibody to compare paxillin-Crk interaction (upper panel) or with an anti-Crk antibody to verify Crk expression (lower panel). The arrow indicates the coprecipitating pool of paxillin. WB, Western blotting; IP, immunoprecipitation.

The fact that NGF-induced c-Crk II Tyr222 phosphorylation precedes paxillin phosphorylation predicts that c-Crk II may initially dissociate from an existing pool of tyrosine-phosphorylated paxillin. To test this hypothesis, wild-type c-Crk II or c-Crk Y222F were transiently expressed in PC12-615 cells using recombinant Crk-expressing retrovirus (Fig. 5D). In the cells overexpressing wild-type c-Crk II, a complex of c-Crk II and paxillin was detectable in unstimulated cells, and this complex dissociated within 2 min of NGF addition (Fig. 5D, lanes 2 and 3). In contrast, expression of c-Crk Y222F promoted Crk/paxillin association in the basal state and resulted in hyperphosphorylation of paxillin. In agreement with the results in 293T cells, NGF stimulation of these cells failed to induce the dissociation of paxillin from the anti-Crk immunocomplex (Fig. 5D, lanes 4 and 5).

Mutation of c-Crk II Tyr222 Impairs Cellular Adhesion and NGF-induced Neuritogenesis-- The enhanced interaction of hyperphosphorylated paxillin with c-Crk Y222F could either positively or negatively modulate the cytoskeletal dynamics that are critical for NGF-induced neuritogenesis. To examine the effects of c-Crk Y222F overexpression during NGF-inducible neuritogenesis, wild-type c-Crk II and c-Crk Y222F were expressed in PC12 cells by stable gene transfer. Independent PC12 cell lines overexpressing c-Crk II or c-Crk Y222F at 2-3 times the endogenous c-Crk II levels were clonally expanded (Fig. 6A). Whereas parental PC12 cells or c-Crk II-overexpressing PC12 cells demonstrated rapid c-Crk II tyrosine phosphorylation following NGF stimulation, no endogenous c-Crk II tyrosine phosphorylation was observed in NGF-treated c-Crk Y222F-expressing cells (Fig. 6A), a result confirmed in several independent clones. When NGF-stimulated neurite outgrowth was compared between the three cell types, we found that the c-Crk Y222F-expressing PC12 cells tended to form aggregates with short or no visible neuritic processes, even after 72 h of NGF treatment (Fig. 6B, panel vii). To determine if paxillin localization was perturbed upon c-Crk Y222F expression, immunolocalization of paxillin was performed. As shown in Fig. 6B, punctate F-actin and paxillin staining were localized to the leading edges of the growth cones in cells expressing wild-type c-Crk II (panels ii and v for native PC12 cells and panels iii and vi for c-Crk II-expressing PC12 cells), consistent with the formation of normal focal contacts. With Y222F c-Crk-expression, paxillin localized diffusely in the cytoplasm, particularly in the perinuclear region, but lacked discernable localization in the short processes (Fig. 6B, panels viii and ix).


View larger version (96K):
[in this window]
[in a new window]
 
Fig. 6.   c-Crk Y222F inhibits NGF-dependent neuritogenesis and causes paxillin mislocalization. A, Wild-type and c-Crk Y222F-expressing PC12 cells were treated for 5 min in the presence or absence of 100 ng/ml NGF as indicated. The lysates were immunoblotted with anti-Crk to verify Crk overexpression or immunoprecipitated with anti-Crk antibodies to detect phosphorylated c-Crk II (anti-Tyr(P) (anti-pTyr) panel). B, PC12 cells (panels i-iii), c-Crk II-expressing PC12 cells (panels iv-vi), or c-Crk Y222F-expressing PC12 cells (panels vii-ix) were treated with 50 ng/ml NGF for 72 h (top 3 panels) or 36 h (bottom 6 panels). For immunofluorescence, cells were fixed, permeabilized, and stained with either rhodamine-conjugated phalloidin (panels ii, v, and viii) or anti-paxillin monoclonal antibody (panels iii, vi, ix). WB, Western blotting; IP, immunoprecipitation.

The possible mislocalization of paxillin in c-Crk Y222F-expressing PC12 cells together with the established role of paxillin and c-Crk II in focal adhesion assembly and in integrin-mediated cellular adhesion prompted us to evaluate the effects of Y222F c-Crk on cell attachment and adherence to extracellular matrix (Fig. 7). Previous studies have documented that PC12 cells readily attach to poly-D-lysine and collagen IV (45). Although attachment to collagen IV requires integrin activation, cells attach to poly-D-lysine in an integrin-independent manner (50). In a quantitative cell attachment assay, PC12 cells were plated on either BSA, poly-D-lysine, or collagen IV in the presence of 50 ng/ml NGF for 6 h. (Fig. 7A). Native PC12 cells adhered to collagen IV and exhibited 85% attachment when normalized to adherence on poly-D-lysine (Fig. 7A). In contrast, c-Crk Y222F-expressing PC12 cells were significantly impaired in their ability to attach to collagen IV (approximately 25%) yet maintained ability to adhere to poly-D-lysine. Interestingly, PC12 cells overexpressing wild-type c-Crk II also exhibited a modest decrease in adhesion on collagen IV, despite apparently normal neuritogenesis. Since a decrease in substrate adhesion might have a direct effect on cellular flattening, an area/height ratio analysis was carried out as an independent criterion for assessing the effect of c-Crk Y222F on PC12 cytoskeleton (Fig. 7B). Using BSA-DiI (which stains plasma membranes) followed by optical sectioning with confocal microscopy, we found that both native and c-Crk II-expressing PC12 cells exhibit similar area/height ratios, whereas c-Crk Y222F expression changes the cell shape from flat and polygonal to round, as revealed by the decrease (>50%) in area/height ratios.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 7.   c-Crk Y222F impairs integrin-mediated cell attachment and causes detachment of PC12 cells. A, control PC12 cells, c-Crk II, or c-Crk Y222F-expressing PC12 cells were plated for 6 h on either 1.0 mg/ml BSA or 2 mg/ml collagen IV-coated surfaces as indicated and assayed for attachment by a quantitative cell attachment assay. Each value represents the mean of determinations made in triplicate wells performed in parallel and expressed as the percentage of attachment to the positive control (i.e. poly-D-lysine). Vertical error bars indicate S.D. B, serial x-y confocal sections obtained from parental PC12 cells, c-Crk II expressing PC12 cells, or c-Crk Y222F-expressing PC12 cells (from left to right). The smaller panels are cross-section representatives, and the area to height ratios are indicated by the numbers below each panel. C, PC12 cells were infected with recombinant retroviral vectors expressing GFP alone or coexpressing GFP with either wild-type c-Crk II or c-Crk Y222F as in Fig. 6. The percentage of GFP-positive cells that remained adherent versus the percentage removed in the wash were quantified by fluorescence-activated cell sorter analysis gated with a fluorescein isothiocyanate filter. Data are plotted as the average ratio of detached/attached cells plated in triplicate and are the average of two independent experiments. In the inset, GFP-positive cells were FACSorted and collected. Detergent lysates were prepared, and 20 µg of protein was immunoblotted with either anti-GFP or anti-Crk antibodies to demonstrate coexpression. WB, Western blotting.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 8.   A model for the c-Crk II phosphorylation switch. The cycle represents a combination of features that may be attributable to dynamic cytoskeletal changes following NGF stimulation. c-Abl, which is shown in a complex with TrkA (47), transduces an intracellular signal that results in the sequential phosphorylation of c-Crk Tyr222 and paxillin Tyr31 (panel A). In this model, c-Crk Tyr222 is rate-limiting for the dissociation of cellular complexes of c-Crk and paxillin as well as c-Crk and Abl (panel B). Subsequently, a dephosphorylated Crk molecular may associate again with Abl to establish another cycle of Crk/paxillin turnover (panel C).

Because stable cell lines exhibiting defects in cellular adhesion may result in instability of c-Crk expression with passaging, transient overexpression of c-Crk II or c-Crk Y222F in the PC12-615 cells with the marker gene GFP was utilized for further analysis (Fig. 7C). Consistent with the results using stable PC12 transfectants, GFP-positive cells overexpressing c-Crk Y222F exhibited a round morphology compared with those expressing GFP alone (not shown). Similarly, in a quantitative cell attachment assay, the ratio of poorly adherent/attached GFP-positive cells was approximately 3-fold higher in the Crk Y222F-expressing cells compared with the vector alone-infected cells, whereas cells overexpressing wild-type c-Crk II exhibited a modest increase in detachment (a 1.6-fold increase). When GFP-positive gated cells were counter-stained with phosphatidylethanolamine-conjugated annexin V, there was no difference in staining in the GFP-positive and -negative cells, indicating that the loss in cellular adhesion does not result from apoptosis (data not shown).

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In the present study, we have investigated the role of Tyr222 phosphorylation in the c-Crk II adaptor protein and found that c-Crk II phosphorylation is critical for normal cytoskeletal signaling and cellular adhesion. Overexpression of c-Crk Y222F in cells stabilized an association between c-Crk II and paxillin and c-Abl, resulting in persistent complex formation of these proteins and hyperphosphorylation of paxillin and led to a defect in cell adhesion and neuritogenesis in PC12 cells. We propose that sequential tyrosine phosphorylation of c-Crk II on Tyr222 and paxillin on Tyr31, induced following NGF stimulation, permits rapid turnover of multiprotein complexes that regulate cytoskeletal plasticity and actin reorganization, a strategy that may also be adopted for other cell type-specific morphogenic events.

The mechanism by which c-Crk II promotes cell adhesion and migration has been mainly explored in fibroblasts and epithelial cells during adhesion and cell migration along the extracellular matrix (7, 12, 14, 33, 51). In such cells, integrin receptor activation results in tyrosine phosphorylation of p130cas and paxillin, thereby recruiting c-Crk II via its SH2 domain (25). c-Crk II in turn can interact with downstream effectors such as the guanine nucleotide exchange proteins C3G and DOCK180 (11, 52). When coupled, the regulated binding of c-Crk II to p130cas may serve as a regulator of stress fiber formation (13) and cell migration (12, 14), leading to the activation of both JNK- and Rac1-dependent signaling pathways (15, 32, 53, 54). The present findings that c-Crk Y222F overexpression manifests an apparent defect in cytoskeletal organization, despite leading to persistent complex formation between Crk, paxillin, and c-Abl implies that purely inductive signaling is insufficient for the effects of Crk on cellular adhesion and migration. We posit that the effects of c-Crk II on cellular adhesion are determined by a balance of positively and negatively acting signals transmitted through the differential phosphorylation of c-Crk II on Tyr222.

Following stimulation of cells with NGF, we have shown here that the non-receptor tyrosine kinase c-Abl is an intermediary for TrkA-inducible phosphorylation of c-Crk II on Tyr222 and paxillin on Tyr31. Although FAK is clearly implicated in paxillin phosphorylation and in integrin-mediated focal adhesions and cell spreading (30, 51), there is also precedent for FAK-independent pathways in such processes (55). For example, in CML cells or myeloid cells expressing BCR-Abl, CrkL has been shown to link BCR-Abl with paxillin, leading to paxillin phosphorylation on Tyr31 and Tyr118 (56). Moreover, studies in fibroblasts have shown that a pool of cytoplasmic c-Abl associates with and tyrosine phosphorylates paxillin after integrin-dependent adhesion (23). Recent results by Yano et al. shows that c-Abl can form a physical complex with Trk A (47) that may in part explain previous studies showing an association between TrkA and c-Crk II in co-immunoprecipitation studies (57, 58). Interestingly, mapping studies between TrkA and c-Abl indicated that c-Abl interacts with TrkA through the juxtamembrane region of TrkA, a region also known to be required for TrkA-mediated neurite outgrowth (59). In future studies it should be important to examine whether juxtamembrane mutants of TrkA fail to induce c-Crk II and paxillin phosphorylation following NGF stimulation.

The findings that NGF simultaneously induces Tyr222 phosphorylation in c-Crk II and Tyr31 phosphorylation in paxillin suggests that a cyclical model for Crk and paxillin association has important implications in vivo. Early changes in the association of paxillin and c-Crk II and CrkL have also been observed following stimulation of cells with insulin-like growth factor and epidermal growth factor (60, 61). Hence, we propose that the breakdown of focal contacts may occur initially (within 5 min of NGF treatment) and is followed by cyclical turnover of c-Crk II/paxillin complexes (after 5 min of NGF treatment). Even though c-Crk II and paxillin tyrosine phosphorylation appears unchanged at steady state, our model predicts the presence of (i) phosphorylated c-Crk II, which is monomeric, and (ii) dephosphorylated c-Crk II, which complexes with c-Abl and with tyrosine-phosphorylated paxillin (Fig. 8). Thus, in a dynamic equilibrium, c-Abl "regenerates" monomeric c-Crk II via Tyr222 phosphorylation, which results in the dissociation of phospho-c-Crk II from tyrosine-phosphorylated paxillin (SH2-dependent) and from c-Abl (SH3-dependent). Although a definitive proof of this hypothesis may require "real time" analysis, the enhanced association of hyperphosphorylated paxillin and c-Abl with the c-Crk Y222F mutant (this study) is consistent with the dynamic molecular interactions, as suggested by this model. Accordingly, when the pathway required for turnover is impaired upon introduction of the Y222F mutation, c-Abl-mediated phosphorylation of paxillin is not counterbalanced by the formation of phospho-c-Crk II monomer. As a result, phosphorylated paxillin remains associated with c-Crk (Y222F) and, presumably, further phosphorylated by c-Abl within the complex (Fig. 8). Such constitutive tethering of protein complex might also lead to the inability of paxillin to reach a cellular destination, such as focal adhesions, and hence, lead to defects in cellular adhesion and impaired neuritogenesis. Interesting, in a recent study with CrkL, Y207F CrkL, which corresponds to Y222F in c-Crk II, increases the level of paxillin tyrosine phosphorylation compared with native CrkL (18), suggesting there may be functional redundancy of Crk proteins regulating cell adhesion.

The fact that c-Crk Tyr222 phosphorylation disrupts the binding of Crk to both paxillin and c-Abl suggests that such phosphorylation functions to sequester the binding surfaces of both domains in the native structure. Although NMR spectroscopy analysis on c-Crk II indicates the SH2 domain of Crk binds phosphorylated Tyr222 (19) and suggests a conformation change in the Crk SH3 domain, these studies did not address whether the binding affinity of the Crk SH3 domain was changed. The crystal structures of the Src and Hck kinases (62, 63) may also provide insight into how Tyr222 phosphorylation in Crk may function. Indeed, it has long been realized that Src kinases are inhibited by tyrosine phosphorylation in the C-terminal Tyr527 residue (64-66). However, it has been recently shown that intramolecular binding of phosphorylated Tyr527 tail to the SH2 domain indirectly inhibits Src enzymatic activity by facilitating a second intramolecular interaction between the SH3 domain and the Src catalytic domain (SH1) (62). Given the importance of Tyr222 phosphorylation in regulating c-Crk binding affinities, detailed structural studies are warranted to ascertain how phosphorylation of Tyr222 affects the interdomain structures of the SH2 and SH3 domains.

Given the cyclical nature of c-Crk II/paxillin binding and turnover, an equally important issue pertains to the dephosphorylation of c-Crk II Tyr222 and of paxillin. Currently, however, there is no known Crk-specific phosphatase, despite the finding that treatment of cells with the tyrosyl phosphatase inhibitor sodium vanadate phosphatase increases c-Crk II tyrosine phosphorylation in vivo.2 In contrast, numerous phosphatases, including Shp2, PTP-PEST, PTP-alpha , LAR, and PTEN, have been implicated in the regulation of cell adhesion and migration by dephosphorylating focal adhesions proteins such as FAK, p130cas, and paxillin (67-71). For example, fibroblasts derived from PTP-PEST (-/-) mice display hyperphosphorylated paxillin and a concomitant decrease in cell adhesion and motility, suggesting that PTP-PEST plays a role in the breakdown of focal adhesions (68). In the c-Crk Y222F-expressing PC12 cells, hyperphosphorylated paxillin is unable to interact with focal contacts and actin microfilaments in the lamellipodia of advancing growth cones. Therefore, like c-Crk II, the phosphorylation status of paxillin is tightly coupled to cytoskeletal dynamics, since both hypo- and hyperphosphorylated paxillin might be disruptive for focal adhesion complex formation. In view of the phosphotyrosine-dependent on/off interaction between paxillin and c-Crk II, it will be interesting to determine whether the putative PTPases specific for c-Crk II may also play a direct role in reversing paxillin phosphorylation.

In summary, we propose a model based on the differential tyrosine phosphorylation of c-Crk II to account in part for rapid and dynamic cytoskeletal reorganization following growth factor stimulation. Our data are consistent with the emerging evidence that c-Crk II- and Crk-associated proteins may exert specialized functions in the generation, dissipation, and regeneration of mechanochemical force required for cell shape changes. Future research will focus on mutations that disrupt the Crk/paxillin/Abl circuit to specifically address the complexity of molecular cross-talk underscored by the present study.

    ACKNOWLEDGEMENTS

We thank Christopher Turner, Steven Hanks, David Baltimore, David Kaplan, Hisataka Sabe, Tohru Ouchi, and Tadashi Yamamoto for generous gifts of reagents and Kathrin Kirsch and Hidesaburo Hanafusa for critical comments on the manuscript.

    FOOTNOTES

* This research was supported in part by National Institutes of Health Grant GM55760 and a Muscular Dystrophy Association grant (to R. B. B.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ These authors contributed equally.

|| Supported by Public Health Service Grant NS30687 and a fund from the March of Dimes.

Dagger Dagger To whom correspondence should be addressed: The New Jersey Medical School, 185 S. Orange Ave., MSB, E-647, University Heights, Newark, NJ 07103-2714. Tel.: 973-972-4497; E-mail: birgera@umdnj.edu.

Published, JBC Papers in Press, May 23, 2000, DOI 10.1074/jbc.M000711200

2 M. Escalante and R. B. Birge, unpublished result.

    ABBREVIATIONS

The abbreviations used are: SH2, Src homology 2; FAK, focal adhesion kinase; NGF, nerve growth factor; DMEM, Dulbecco's modified Eagle's medium; GFP, green fluorescent protein; PBS, phosphate-buffered saline; BSA, bovine serum albumin.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Birge, R. B., Knudsen, B., Besser, D., and Hanafusa, H. (1996) Genes Cells 1, 595-613
2. Buday, L. (1999) Biochim. Biophys. Acta 1422, 187-204
3. Feller, S. M., Posern, G., Voss, J., Kardinal, C., Sakkab, D., Zheng, J., and Knudsen, B. (1998) J. Cell. Physiol. 177, 535-552
4. Hempstead, B. L., Birge, R. B., Fajardo, J. E., Glassman, R., Mahadeo, D., Kraemer, R., and Hanafusa, H. (1994) Mol. Cell. Biol. 14, 1964-1971
5. Teng, K. K., Courtney, J. C., van Bergen Henegouwen, P., Birge, R. B., and Hempstead, B. L. (1996) Mol. Cell. Neurosci. 8, 157-170
6. Weinstein, D. E., Dobrenis, K., and Birge, R. B. (1999) Dev. Brain Res. 116, 29-39
7. Nievers, M. G., Birge, R. B., Greulich, H., Verkleij, A. J., Hanafusa, H., and van Bergen Henegouwen, P. (1997) J. Cell Sci. 110, 389-399
8. Altun-Gultekin, Z. F., Chandriani, S., Bougeret, C., Ischizaki, T., de Graaf, P., van Bergen Henegouwen, P., Hanafusa, J. A., Wagner, J. A., and Birge, R. B. (1998) Mol. Cell. Biol. 18, 3044-3058
9. Reichman, C., Mayer, B., Keshav, S., and Hanafusa, H. (1992) Cell Growth Differ. 3, 451-460
10. Hoeve, J. T., Morris, C., Heisterkamp, M., and Groffen, J. (1993) Oncogene 8, 2469-2474
11. Kiyokawa, E., Hashimoto, Y., Kobayashi, S., Sugimura, H., Kurata, T., and Matsuda, M. (1998) Genes Dev. 12, 3331-3336
12. Cherish, D. A., Leng, J., and Klemke, R. L. (1999) J. Cell Biol. 146, 1107-1116
13. Nakashima, N., Rose, D. W., Xiao, S., Egawa, K., Martin, S. S., Haruta, T., Saltiel, A. R., and Olefsky, J. M. (1999) J. Biol. Chem. 274, 3001-3008
14. Klemke, R. L., Leng, J., Molander, R., Brooks, P. C., Vuori, K., and Cheresh, D. A. (1998) J. Cell Biol. 140, 961-972
15. Oktay, M., Wary, K. K., Dans, M., Birge, R. B., and Giancotti, F. G. (1999) J. Cell Biol. 145, 1461-1469
16. Matsuda, M., Tanaka, S., Nagata, S., Kojima, A., Kurata, T., and Shibuya, M. (1992) Mol. Cell. Biol. 12, 3482-3489
17. Feller, S. M., Knudsen, B., and Hanafusa, H. (1994) EMBO J. 13, 2341-2351
18. Senechal, K., Heaney, C., Druker, B., and Sawyers, C. L. (1998) Mol. Cell. Biol. 18, 5082-5090
19. Rosen, M. K., Yamazaki, T., Gish, G. D., Kay, C. M., Pawson, T., and Kay, L. E. (1995) Nature 374, 477-479
20. Thomas, J. E., Soriano, P., and Brugge, J. S. (1991) Science 254, 568-571
21. Guan, J. L., and Shalloway, D. (1992) Nature 358, 690-692
22. Lev, S., Moreno, H., Martinez, R., Canoll, P., Peles, E., Musaacchio, J. M., Plowman, G. D., Rudy, B., and Schlessinger, J. (1995) Nature 376, 737-744
23. Lewis, J. M., and Schwartz, M. A. (1998) J. Biol. Chem. 273, 14225-14230
24. Schaller, M. D., Hildebrand, J. D., Shannon, J. D., Fox, J. W., Vines, R. R., and Parsons, J. T. (1994) Mol. Cell. Biol. 14, 1680-1688
25. Giancotti, F. G., and Rouslahti, E. (1999) Science 285, 1028-1032
26. Turner, C. E., and Miller, J. T. (1994) J. Cell Sci. 107, 1583-1591
27. Nojima, Y., Morino, N., Mimura, T., Hamasaki, K., Furuya, H., Sakai, R., Sato, T., Tachibana, K., Morimoto, C., Yazaki, Y., and Hirai, H. (1995) J. Biol. Chem. 270, 15398-15402
28. Schlaepfer, D. D., Hauck, C. R., and Sieg, D. J. (1999) Prog. Biophys. Mol. Biol. 71, 435-478
29. Birge, R., Fajardo, J., Reichman, C., Shoelson, S., Songyang, Z., Cantley, L., and Hanafusa, H. (1993) Mol. Cell. Biol. 13, 4648-4656
30. Schaller, M. D., and Parsons, J. T. (1995) Mol. Cell. Biol. 15, 2635-2645
31. Sakai, R., Iwamatsu, A., Hirano, N., Ogawa, S., Tanaka, T., Mano, H., Yazaki, Y., and Hirai, H. (1994) EMBO J. 13, 3748-3756
32. Kiyokawa, E., Hashimoto, Y., Kurata, T., Sugimura, H., and Matsuda, M. (1998) J. Biol. Chem. 273, 24479-24484
33. Petit, V., Boyer, B., Lentz, D., Turner, C. E., Thiery, J. P., and Valles, V. M. (2000) J. Cell Biol. 148, 957-970
34. Abedi, H., Dawes, K. E., and Zachary, I. (1995) J. Biol. Chem. 270, 11367-11376
35. Casamassima, A., and Rozengurt, E. (1998) J. Biol. Chem. 273, 26149-26156
36. Ojaniemi, M., and Vuori, K. (1997) J. Biol. Chem. 272, 25993-25998
37. Greene, L., and Tischler, A. (1982) Adv. Cell. Neurobiol. 3, 373-414
38. Altun-Gultekin, Z. F., and Wagner, J. A. (1996) J. Neurosci. Res. 44, 308-327
39. Ribon, V., and Saltiel, A. R. (1996) J. Biol. Chem. 271, 7375-7380
40. Hashimoto, Y., Katayama, H., Kiyokawa, E., Ota, S., Kurata, T., Gotoh, N., Otsuka, N., Shibata, M., and Matsuda, M. (1998) J. Biol. Chem. 273, 17186-17191
41. Hempstead, B. L., Rabin, S. J., Kaplan, L., Reid, S., Parada, L. F., and Kaplan, D. R. (1992) Neuron 9, 883-896
42. Mayer, B. J., Hirai, H., and Sakai, R. (1995) Curr. Biol. 5, 296-305
43. Ben-Neriah, Y., Bernards, A., Paskind, M., Daley, G. Q., and Baltimore, D. (1986) Cell 44, 577-586
44. Mayer, B. J., and Baltimore, D. (1994) Mol. Cell. Biol. 14, 2883-2894
45. Tomaselli, K. J., Damsky, C. H., and Reichardt, L. F. (1987) J. Cell Biol. 105, 2347-2358
46. Melamed, I., Turne, C. E., Aktories, K., Kaplan, D. R., and Gelfand, E. W. (1995) J. Exp. Med. 181, 1071-1079
47. Yano, H., Cong, F.., Birge, R. B., Goff, S. G., and Chao, M. V. (2000) J. Neurosci. Res. 59, 356-364
48. Hildebrand, J. D., Schaller, M. D., and Parsons, J. T. (1995) Mol. Biol. Cell. 6, 637-647
49. Ilac, D., Furuta, S., Kanazawa, S., Takeda, N., Sobue, K., Nakatsuji, N., Nomura, S., Fujimoto, J., Okada, M., Yamamoto, T., and Alzawa, S. (1995) Nature 377, 539-544
50. Hynes, R. O. (1992) Cell 69, 11-25
51. Richardson, A., Malik, R. K., Hildebrand, J. D., and Parsons, J. T. (1997) Mol. Cell. Biol. 17, 6906-6914
52. Tanaka, S., Ouchi, T., and Hanafusa, H. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 2356-2361
53. Dolfi, F., Garcia-Guzman, M., Ojaniemi, M., Nakamura, H., Matsuda, M., and Vuori, K. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 15394-15399
54. Ling, P., Yao, Z., Meyer, C. F., Wang, X. S., Oehrl, W., Feller, S. M., and Tan, T. H. (1999) Mol. Cell. Biol. 19, 1359-1368
55. Sakai, R., Nakamoto, T., Ozawa, K., Aizawa, S., and Hirai, H. (1997) Oncogene 14, 1419-1426
56. Salgia, R., Uemura, N., Okuda, K., Li, J.-L., Pisick, E., Sattler, M., de Jong, R., Druker, B., Heisterkamp, N., Chen, J., Groffen, L. B., and Griffin, J. D. (1995) J. Biol. Chem. 270, 29145-29150
57. Torres, M., and Bogenmann, E. (1996) Oncogene 11, 77-86
58. Meakin, S. O., MacDonald, J. I. S., Gryz, E. A., Kubu, C. J.,